I-Mab
NASDAQ:IMAB

Watchlist Manager
I-Mab Logo
I-Mab
NASDAQ:IMAB
Watchlist
Price: 4.07 USD 2.01%
Market Cap: 332.4m USD

Net Margin
I-Mab

0%
Current
-206%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-37.7m
/
Revenue
0

Net Margin Across Competitors

Country Company Market Cap Net
Margin
CN
I-Mab
NASDAQ:IMAB
332.4m USD N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
395.1B USD
4%
US
Amgen Inc
NASDAQ:AMGN
174.1B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
148.5B USD
28%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.4B USD
31%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.7B USD
32%
AU
CSL Ltd
ASX:CSL
85.8B AUD
19%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.5B USD
1%
NL
argenx SE
XBRU:ARGX
44.3B EUR
43%
No Stocks Found

I-Mab
Glance View

Market Cap
332.4m USD
Industry
Biotechnology

I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.

IMAB Intrinsic Value
Not Available
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-37.7m
/
Revenue
0
What is the Net Margin of I-Mab?

Based on I-Mab's most recent financial statements, the company has Net Margin of 0%.

Back to Top